3,4-dihydroquinoline-1(2H)-sulphonamide | 1152573-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3,4-dihydroquinoline-1(2H)-sulphonamide
• 英文别名: 3,4-dihydroquinoline-1(2H)-sulfonamide；1,2,3,4-Tetrahydroquinoline-1-sulfonamide；3,4-dihydro-2H-quinoline-1-sulfonamide
• CAS: 1152573-61-9
• 化学式: C₉H₁₂N₂O₂S
• mdl: MFCD11104187
• 分子量: 212.272
• InChiKey: XBVDUBWHMSFQLE-UHFFFAOYSA-N

物化性质

• 沸点：
  386.9±35.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-dihydroquinoline-1(2H)-sulphonamide 、 5-chloro-4-(cyclopentylmethoxy)-2-fluorobenzoic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以53 mg的产率得到5-chloro-4-(cyclopentylmethoxy)-N-((3,4-dihydroquinolin-1(2H)-yl)sulfonyl)-2-fluorobenzamide
  参考文献：
  名称：

  [EN] SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME
  [FR] INHIBITEURS DE CANAUX SODIQUES ET LEURS PROCÉDÉS DE CONCEPTION

  摘要：

  The invention provides compounds of formulae I, II, Ila, and III, as described herein, and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.

  公开号：

  WO2023028077A1
• 作为产物：
  描述：

  在 甲醇 、 乙酰氯 作用下， 生成 3,4-dihydroquinoline-1(2H)-sulphonamide
  参考文献：
  名称：

  Diversely substituted sulfamides for fragment-based drug discovery of carbonic anhydrase inhibitors: synthesis and inhibitory profile

  摘要：

  DOI：

  10.1080/14756366.2022.2051023

文献信息

• SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS
  申请人：Diaz-Fernandez Jose Luis

  公开号：US20090030013A1

  公开（公告）日：2009-01-29

  The present invention refers to substituted tetrahydro-quinoline-sulfonamide compounds of general formula (I): a method for their preparation, a medicament comprising these compounds and the use of substituted tetrahydro-quinoline-sulfonamide compounds for the preparation of medicaments for 5-HT 6 receptor regulation as well as for the treatment of disorders related thereto.

  本发明涉及通式（I）的取代四氢喹啉磺胺化合物，其制备方法，包含这些化合物的药物以及利用取代四氢喹啉磺胺化合物制备用于5-HT6受体调节的药物以及相关疾病治疗的用途。
• Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP2016943B1

  公开（公告）日：2011-02-23
• Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180244611A1

  公开（公告）日：2018-08-30

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
• US7964603B2
  申请人：——

  公开号：US7964603B2

  公开（公告）日：2011-06-21
• [EN] MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE<br/>[FR] MODULATEURS DE PROTÉINE RÉGULATRICE DE CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE SARL

  公开号：WO2018154519A1

  公开（公告）日：2018-08-30

  The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention. In one embodiment, the compound is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein A1 is selected from the group consisting of X1, X2, X3, X4; R1, R2A, R2B, R2C, R2D, R3, R4,R5A, R5B, R5C, R5D, R6A, R6B, R6C, R6D, R7, R8, R9, R10, R11, R12, R13, and R14 are as described herein.